Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Tarisai Nyahoda

Geriatric Medicine Chesterfield, MO Medical Doctor

NPI 1053971846 CMS profile 6815680

222 S Woods Mill Rd, Chesterfield, MO 63017

Open in the dashboard

General payments

$155

3 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Tarisai Nyahoda of Chesterfield, MO is reported in the CMS Open Payments database as having received $155 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $17 1
2020 General $125 1
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarisai Nyahoda
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Tarisai Nyahoda were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Tarisai Nyahoda Geriatric Medicine median Middle half National median
2019 $12 $122 $40–$435 $163
2020 $125 $98 $25–$349 $114
2021 $17 $125 $34–$441 $132
2022 $0 $124 $36–$408 $149
2023 $0 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $125 1 payment
  2. Arbor Pharmaceuticals, Inc. $17 1 payment
  3. Lilly USA, LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $155 3 payments
Products named General payments · program years 2019–2021
  1. CALQUENCE $125 1 payment
  2. Horizant $17 1 payment
  3. TALTZ $12 1 payment
  4. OLUMIANT $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

3,110

Median for Geriatric Medicine: 2,306

Drug cost

$175,980

Median for Geriatric Medicine: $150,713

Branded share of claims

16.8%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 132 $83,153
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 44 $14,278
Myrbetriq Mirabegron Brand 27 $12,780
Multaq Dronedarone Hcl Brand 12 $10,248
Gemtesa Vibegron Brand 11 $5,765
Lumigan Bimatoprost Brand 16 $4,149
Memantine Hcl Generic 53 $3,554
Duloxetine Hcl Generic 41 $3,460
Rosuvastatin Calcium Generic 59 $2,974
Ezetimibe Generic 16 $2,869

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$51,249

Medicare's payments for the services billed

Medicare patients

248

Average age 84

Services billed

589

168 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Alzheimer's or dementia 44%
Chronic kidney disease 40%
Depression 37%
Atrial fibrillation 36%
Osteoporosis 35%
Heart failure 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record